PATENT CLAIM ANALYSIS

Application Number: 16053265
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["514", "255000"]

Abstract:
This disclosure relates to pyrazoline dihydroquinolone derivatives, pharmaceutical compositions, and uses. In certain embodiments, the compounds are selective NMDA receptor inhibitors and are useful in therapeutic methods related thereto. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a compound of the following formula: or salts, esters, or prodrugs thereof, as provided herein.

Claim (Index 15):
The method of  claim 14 , wherein the disease or condition is cognitive impairment, a neurodegenerative disease, pain, depression, schizophrenia, attention deficit hyperactivity disorder, ischemia, or addiction.

Metadata:
- Claim Count in Document: 16.0
- Percentile: 96.0
- Lexical Diversity: 1.44444
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15558971', '15503875', '15428710', '16046332', '12554134']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.802717022944944
- 35 USC 102 Novelty (BERT): 0.5115363025776185
- Combined Prediction Score: 0.7735989509082114
- Mean Citation Score: 289.7414720000001
- Max Citation Score: 300.38727
- Similarity Product: 242.9699771803594

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test